-+ 0.00%
-+ 0.00%
-+ 0.00%

C4 Therapeutics Positions Cemsidomide As Potential Best-In-Class Myeloma Therapy While Expanding Discovery Efforts Beyond Oncology

Benzinga·01/14/2026 12:08:06
Listen to the news
  •  Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg
  • Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026
  • Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways
  • Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points